stock
QUIT · ACHIEVE LIFE SCIENCES, INC.
No insider buys or sales filed in 90 days; last 8-K filed Nov 10: results.
Follow QUIT freePrice
Loading the QUIT chart…
Chart by TradingView
The business
What the company does and what it reports, from its SEC filings.
What it is
We are a late-stage clinical specialty pharmaceutical company with the sole mission to address the global nicotine dependence epidemic through the development and commercialization of cytisinicline. There are an estimated 29 million adults in the United States alone who smoke combustible cigarettes and an estimated 17 million adults in the United States who utilize e-cigarettes. Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually. More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke. Our primary focus is to address this global epidemic.
From the 10-K for the fiscal year ended Dec 31, 2025, filed Mar 24, 2026.
Read the 10-K on SEC- Sector
- Life Sciences (SEC office)
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Employees
- Not stated in the 10-K.
- Headquarters
- Seattle, WA
- Incorporated in
- DE
- Fiscal year ends
- December
- Exchange
- Nasdaq
- Fractional shares
- Yes
- Listed options
- Yes
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Formerly
- ONCOGENEX PHARMACEUTICALS, INC. (until 2017); SONUS PHARMACEUTICALS INC (until 2008)
- Shares outstanding
- 110,034,457 as of Nov 10, 2026 (XBRL frame CY2026Q3I)
- Filer (SEC EDGAR)
- EDGAR filing index
Key stats
Valuation and the ratios that use the live price are free with an account.
Start free to see thisDeep value
- NCAV
- $177.72M
- NCAV per share
- $1.62
- NNWC
- $34.04M
- NNWC per share
- $0.31
Expectations
- Free cash flow, FY2025
- -$49.47M
- Free cash growth, last 5 years
- —
- Revenue growth, last 5 years
- —
Margins
- Gross
- —
- Operating
- —
- Net
- —
Returns
- ROE
- -61.8%
- ROA
- -54.1%
Health
- Current ratio
- 10.5x
- Debt/equity
- —
Trailing twelve months to Sep 30, 2026; balance sheet at Sep 30, 2026.
Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit (not reported by this company) | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| Sep 30, 2026 | — | —Gross profit: unreported by this company. | — | -$12.11M | |
| Jun 30, 2026 | — | —Gross profit: unreported by this company. | — | -$74.77M | |
| Mar 31, 2026 | — | —Gross profit: unreported by this company. | — | -$10.17M | |
| Dec 31, 2025 | — | —Gross profit: unreported by this company. | — | -$14.66M | Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. |
| Sep 30, 2025 | — | —Gross profit: unreported by this company. | — | -$14.44M | |
| Jun 30, 2025 | — | —Gross profit: unreported by this company. | — | -$12.72M | |
| Mar 31, 2025 | — | —Gross profit: unreported by this company. | — | -$12.83M | |
| Dec 31, 2024 | — | —Gross profit: unreported by this company. | — | -$12.36M | Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. |
- Cash
- $59.74M
- Debt
- —
- Net cash
- —
- Current assets
- $203.41M
- Current liabilities
- $19.39M
- Working capital
- $184.03M
- Total liabilities
- $25.69M
- Assets
- $206.42M
- Equity
- $180.73M
Balance as of Sep 30, 2026.
SEC data as of Nov 17, 2026
Earnings moves
| Report | Reaction day |
|---|---|
| Aug 11, 2026 After the close | Aug 12, 2026 |
| May 12, 2026 Before the open | May 12, 2026 |
| Mar 24, 2026 Before the open | Mar 24, 2026 |
| Nov 6, 2025 Before the open | Nov 6, 2025 |
How the price moved after each report: Start free to see this
Next report: Nov 19, 2026
What happened after past reports, not a forecast. Report dates from SEC 8-K results filings (Item 2.02) since Oct 6, 2025; moves from daily closes.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | — | -$54.65M | -$49.47M |
| Dec 31, 2024 | — | — | -$39.83M | — |
| Dec 31, 2023 | — | — | -$29.82M | -$24.50M |
| Dec 31, 2022 | — | — | -$42.35M | — |
| Dec 31, 2021 | — | — | -$33.15M | — |
| Dec 31, 2020 | — | — | -$14.73M | -$13.49M |
| Dec 31, 2019 | $0 | — | -$16.39M | -$15.27M |
| Dec 31, 2018 | $0 | — | -$12.69M | -$10.67M |
| Dec 31, 2017 | — | — | -$10.58M | — |
| Dec 31, 2016 | — | — | -$1.23M | -$248,000 |
What it filed
Material events and 5% ownership filings from the last year.
Company filings
since Tue May 12 · 1 offering filing in 12 months · since Fri Aug 14
events
5% owners ()
Venrock Healthcare Capital Partners III, L.P.
Stake update
Alyeska Investment Group, L.P.
Stake update
Logos Global Management LP
Stake update
Logos Global Management LP
Stake update
Logos Global Management LP
Passive stake
Owners and trading
Insider, politician and fund moves, short interest, and the volume traded off the exchange.
Insiders, politicians and funds
Insider trades, last 90 days
No insider buys or sales filed in the last 90 days.
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
None of the tracked funds held this at their last 13F.
Short interest
Easy to borrow
Off-exchange short volume, 20 days
73.0%
Through Nov 16, 2026
Of the volume reported to FINRA's off-exchange facilities, market makers' hedging included. It is not short interest.
Short interest and short volume: FINRA
Off-exchange and dark pools
No off-exchange data
Members see
- Signals: which strategies fired on QUIT, and the evidence behind each
- Options positioning: the levels dealers are hedged around
- Technicals: trend and momentum readings
- Earnings moves: how the price moved after each report
- News: stories counted once across outlets
nakagai
Signals on QUIT come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Follow QUIT free
Comments · 0
No comments yet.